Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact

Science: general issues --- Physiology --- Insect --- Immune responses --- Modulation --- Interaction --- pest

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Schistosomiasis is a severe parasitic disease, endemic in 74 developing countries with up to 600 million people, including many children, infected and 800 million at risk of contracting the disease following infection with Schistosoma mansoni, S. haematobium or S. japonicum. Disease burden is estimated to exceed 70 million disability-adjusted life-years, and leads to remarkably high YLD (years lived with disability) rates. Even more importantly, people with schistosomiasis are highly susceptible to malaria, tuberculosis and hepatic and acquired immunodeficiency viruses. There is only one drug, praziquantel, currently available for treatment and it has high efficacy, low cost, and limited side effects. However, only 13% of the target population has received the drug, and those treated are at continuous risk of reinfection necessitating repeated drug administration and the emergence of drug resistant parasites is a constant threat. There currently is no vaccine. While the target of >40% protection has been achieved with some molecules such as excretory-secretory proteins including calpain, glyceraldehyde 3-phosphate dehydrogenase, and cysteine peptidases, very recent articles reiterate the findings published during the last 2 decades of the last century, contradicting the established data of the pioneers of schistosome biology. A consensus should be reached without delay, in order to propose collaborative independent experiments and proceed ahead to pre- and clinical trials with efficacious candidate vaccine molecules. The proposed plan aims to finally reach an objective and fruitful agreement , via inviting established and young researchers from the United States, Brazil, China, Australia, and Europe who are working with different vaccine antigens, adjuvants, and approaches for immunization against S. mansoni, S. haematobium, and S. japonicum. It is hoped that the forum will end with a very few candidate antigens and a consensus approach regarding target immune responses, thus leading to encouraging the World Health Organization and other international foundations to sponsor the development and implementation of the urgently required, yet still elusive, vaccine for preventing and eliminating the transmission of schistosomiasis.

Schistosomiasis --- Schistosoma mansoni --- Schistosoma haematobium --- Type 2 cytokines --- Vaccine --- Immune responses --- Schistosoma japonicum --- Vaccine candidates

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Schistosomiasis is a severe parasitic disease, endemic in 74 developing countries with up to 600 million people, including many children, infected and 800 million at risk of contracting the disease following infection with Schistosoma mansoni, S. haematobium or S. japonicum. Disease burden is estimated to exceed 70 million disability-adjusted life-years, and leads to remarkably high YLD (years lived with disability) rates. Even more importantly, people with schistosomiasis are highly susceptible to malaria, tuberculosis and hepatic and acquired immunodeficiency viruses. There is only one drug, praziquantel, currently available for treatment and it has high efficacy, low cost, and limited side effects. However, only 13% of the target population has received the drug, and those treated are at continuous risk of reinfection necessitating repeated drug administration and the emergence of drug resistant parasites is a constant threat. There currently is no vaccine. While the target of >40% protection has been achieved with some molecules such as excretory-secretory proteins including calpain, glyceraldehyde 3-phosphate dehydrogenase, and cysteine peptidases, very recent articles reiterate the findings published during the last 2 decades of the last century, contradicting the established data of the pioneers of schistosome biology. A consensus should be reached without delay, in order to propose collaborative independent experiments and proceed ahead to pre- and clinical trials with efficacious candidate vaccine molecules. The proposed plan aims to finally reach an objective and fruitful agreement , via inviting established and young researchers from the United States, Brazil, China, Australia, and Europe who are working with different vaccine antigens, adjuvants, and approaches for immunization against S. mansoni, S. haematobium, and S. japonicum. It is hoped that the forum will end with a very few candidate antigens and a consensus approach regarding target immune responses, thus leading to encouraging the World Health Organization and other international foundations to sponsor the development and implementation of the urgently required, yet still elusive, vaccine for preventing and eliminating the transmission of schistosomiasis.

Schistosomiasis --- Schistosoma mansoni --- Schistosoma haematobium --- Type 2 cytokines --- Vaccine --- Immune responses --- Schistosoma japonicum --- Vaccine candidates

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Immunity --- Immunité --- Immunity. --- Immunologie --- Disease --- Immunoglobulins --- immunology --- Immunité --- Immune Process --- Immune Response --- Immune Processes --- Immune Responses --- Process, Immune --- Response, Immune

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Essentials of Clinical Immunology provides the most up-to-date, core information required to understand diseases with an immunological basis. Clinically focussed, the sixth edition of this classic text presents theoretical and practical information in a simple yet thorough way. Essentials of Clinical Immunology covers the underlying pathophysiology, the signs and symptoms of disease, the investigations required and guidance on the management of patients. Perfect for clinical medical students, junior doctors and medical professionals seeking a refresher in the role of immunology in clinical medicine, this comprehensive text features fully updated clinical information, boxes with key points, real-life case histories to illustrate key concepts and an index of contents at the start of each chapter. A companion website at www.immunologyclinic.com/6thedition provides additional learning tools, including more case studies, interactive multiple-choice questions and answers, all of the photographs and illustrations from the book, links to useful websites, and a selection of review articles from the journal Clinical and Experimental Immunology .

Clinical immunology. --- Immunologie clinique --- Immunity --- Disease --- Immunoglobulins --- immunology --- Immune Process --- Immune Response --- Immune Processes --- Immune Responses --- Process, Immune --- Response, Immune